Neoadjuvant PD1/PD-L1 Blockade Combined with Chemotherapy Associated with High Resectability and Pathological Responses in Borderline Resectable or Unresectable Stage III NSCLC By Ogkologos - June 3, 2025 473 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from a multicentre cohort study Source RELATED ARTICLESMORE FROM AUTHOR Tambotatug Pelitecan Leads to Better Clinical Outcomes than Topotecan Among Patients with Relapsed SCLC After Platinum-based Therapy ESMO Welcomes European Parliament Calls to Strengthen and Protect Europe’s Cancer Workforce No improvement in OS, but more grade 3 or higher AEs with atezolizumab plus SBRT among patients with inoperable early-stage NSCLC MOST POPULAR ESMO Congress 2022, 9-13 September August 22, 2022 Making Important Decisions During Cancer: A Survivor’s Story October 26, 2021 A Phase III Study of Spartalizumab in Combination with Dabrafenib and... January 20, 2022 Learning to Advocate for Yourself – An Important Skill! June 15, 2023 Load more HOT NEWS Volunteering with Pride: Brett’s award-winning involvement with Cancer Research UK Coming Soon: Medicare Drug Price Negotiations Perioperative Durvalumab Plus FLOT Improves OS in Patients with Resectable Gastric... Single Mom Has To Beg For Rides To Doctor For Son...
